Table 3 Multivariate analyses of progression free-survival and overall survival between Del-19and L858R (n = 78)

Covariate

Hazard ratio

95% CI

p-value

 Age (<65 vs ≥65)

1.13

0.89–1.42

0.31

 Gender (Male vs Female)

0.94

0.73–1.19

0.59

 Smoking history (Never vs Ever)

0.88

0.70–1.13

0.32

 Clinical stage (IIIB, IV vs Recurrence)

1.36

0.99–1.93

0.055

 EGFR mutation status (L858R vs Del-19)

0.78

0.62–0.98

*0.033

Covariate

Hazard ratio

95% CI

p-value

 Age (<65 vs ≥65)

1.21

0.87–1.70

0.25

 Gender (Male vs Female)

1.01

0.73–1.38

0.95

 Smoking history (Never vs Ever)

0.97

0.70–1.37

0.86

 Clinical stage (IIIB, IV vs Recurrence)

2.49

1.37–6.20

*0.001

 EGFR mutation status (L858R vs Del-19)

1.14

0.83–1.57

0.43